Receiving a Second Opinion

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, HER2-negative breast cancer.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.

Tecentriq plus chemotherapy did not improve event-free survival in triple-negative breast cancer but increased rate of complete tumor removal.